The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Ustekinumab Found to Be Effective in Adolescents with Psoriasis

Ustekinumab Found to Be Effective in Adolescents with Psoriasis

August 27, 2015 • By Rob Goodier

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Adolescents with moderate to severe psoriasis may respond to the human monoclonal antibody ustekinumab as well as adults, with no unexpected side effects, a new study found.

You Might Also Like
  • Ustekinumab Approved for Use in Adolescents with Plaque Psoriasis
  • Ustekinumab Can Be Used to Safely Treat Teens & More
  • Ustekinumab Improves Spondylitis in Patients with Psoriatic Arthritis

The findings are exciting in part because patients in this age group have limited treatment options, the study’s lead author Dr. Ian Landells, of Memorial University of Newfoundland, Canada, told Reuters Health by email.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In the CADMUS trial, the researchers randomized 110 patients 12 to 17 years old to a standard dose or a half dose of ustekinumab, or a placebo, for 12 weeks. A standard dose is .75 mg/kg for patients that weigh 60 kg or less, 45 mg for those weighing more than 60 up to 100 kg, and 90 mg for those weighing more than 100 kg, taken at baseline, four weeks later and then every 12 weeks.

The placebo group crossed over to ustekinumab after 12 weeks.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

After 12 weeks, 69.4% of the standard-dose group were cleared according to the Physician’s Global Assessment, as were 67.6% of the half-dose group. Only 5.4% of the placebo group was cleared, however, according to an article online Aug. 7 in the Journal of the American Academy of Dermatology.

Similarly, 80.6% of the standard-dose group achieved at least 75% improvement in Psoriasis Area and Severity Index, as did 78.4% of the half-dose group, compared to only 10.8% of the placebo group.

By week 12, 56.8% of the placebo patients reported at least one adverse event, which was more than either of the treatment groups. Sixty weeks after starting the trial, 81.8% of the patients reported side effects.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“Both dosages resulted in robust and sustainable efficacy. However, efficacy was generally higher with the standard dosage across all endpoints, responses were also better sustained over each 12-week dosing interval with the standard dosage, and both dosages had acceptable safety profiles with no new adverse events identified in this adolescent population,” Dr. Landells said.

One of the trial’s limitations is its small size. Even so, Dr. Landells said he hopes the drug gains approval for adolescents in Canada based on the findings.

Janssen Research and Development funded this research and employed four coauthors. Janssen Biotech is manufacturer of Stelara, ustekinumab’s brand name. Six coauthors reported relationships with pharmaceutical companies, some including Janssen.

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Adolescents, Psoriasis, ustekinumab

You Might Also Like:
  • Ustekinumab Approved for Use in Adolescents with Plaque Psoriasis
  • Ustekinumab Can Be Used to Safely Treat Teens & More
  • Ustekinumab Improves Spondylitis in Patients with Psoriatic Arthritis
  • Ustekinumab May Be Effective for Lupus

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)